消癥汤预防骨肿瘤术后复发临床研究

The Clinical Research into Xiaoyu Decoction for Preventing Bone-Tumor Postoperative Recurrence

目的:观察消癥汤预防骨肿瘤术后复发的临床疗效。方法:选择2013年5月—2014年6月收治的60例骨肿瘤患者,随机分为治疗组和对照组,每组各30例。对照组给予常规治疗,治疗组在对照组的基础上联合消癥汤。观察两组患者治疗后2个月、6个月、12个月、18个月以及24个月的肿瘤复发率、KPS评分的变化以及不良反应的发生情况。结果:两组患者术后2个月与6个月的肿瘤复发率比较,差异无统计学意义(P>0.05)。治疗组治疗后12个月、18个月以及24个月的肿瘤复发率均显著低于对照组,差异具有统计学意义(P<0.05);灌注治疗前,两组患者的KPS评分均较低,差异无统计学意义(P>0.05);治疗组治疗后2个月、6个月、12个月、18个月以及24个月的KPS评分均显著高于对照组患者,具有统计学意义(P<0.05)。经过治疗,治疗组患者发生尿频尿急、恶心呕吐、低热以及尿常规异常等不良反应的例数显著低于对照组,差异具有统计学意义(P<0.05),在腹泻以及血尿方面比较,差异无统计学意义(P>0.05)。但两组患者均未出现骨髓抑制、肝肾毒性等严重不良反应。结论:消癥汤治疗骨肿瘤术后患者,能够显著降低肿瘤的复发率,显著提高KPS评分,具有一定的安全性。

Objective： To observe the clinical curative effect of Xiaoyu Decoction（ XYD） on preventing bone-tumor postoperative recurrence. Methods： Sixty patients with bone tumor who were treated in our hospital between May of 2013 and June of 2014 were chosen as the research subjects,and randomly divided into the treatment group and the control group,with 30 cases in each group.The ones in the control group were given routine treatment,while the ones in the treatment group were added XYD based on the treatment of the control group. Then the two groups＇ tumor recurrence rates,KPS scores and the incidence of adverse reactions for after 2 months＇,6 months＇,12 months＇,18 months＇ and 24 months＇ treatment respectively were observed. Results： After 2months＇,and 6 months＇ intravesical instillation respectively,there was no significant difference in tumor recurrence rate（ P〈0. 05）.,after 12 months＇,18 months＇ and 24 months＇ treatment respectively,the tumor recurrence rate of the treatment group was significantly lower than the control group,the difference was statistically significant（ P〈0. 05）. Before intravesical instillation,the two groups＇ patients with KPS score were relatively lower,and the difference was not statistically significant（ P〈0. 05）. After2 months＇,6 months＇,12 months＇,18 months＇ and 24 months＇ treatment respectively,KPS scores were higher than those of the control group,and all the differences between them had statistical significance（ P〈0. 05）. After the treatment,the number of cases in the treatment group which suffered frequent urination,nausea and vomiting,fever and abnormal urine and other adverse reactions was significantly lower than the control group,and the difference was statistically significant（ P〈0. 05）; In terms of diarrhea and hematuria,there were no statistically significant differences（ P〉0. 05）. There were no serious adverse reactions such as bone marrow suppression,liver and kidney toxicity in the two groups. Conclusion： In terms of treating postoperative patients with bone tumor,XYD can significantly reduce the recurrence rate of tumor,improve the KPS score,and has a certain degree of safety.